Trial record 3 of 5 for:
alemtuzumab | Interventional Studies | multiple sclerosis | Phase 3
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (CARE-MS I)
This study has been completed.
Sponsor:
Genzyme
Collaborator:
Bayer
Information provided by (Responsible Party):
Genzyme
ClinicalTrials.gov Identifier:
NCT00530348
First received: September 13, 2007
Last updated: May 31, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | May 2011 |
| Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Certification or Request for Extension to Delay Results Received: | May 31, 2012 |